Players in the diabetes space are gearing up to head to Philadelphia June 8-12 for the 72nd annual conference of the American Diabetes Association (ADA); analysts and investors are paying close attention to a few classes – particularly basal insulins, Glucagon like peptide-1s (GLP-1) and Sodium Glucose Transport Protein-2s (SGLT-2).
While Sanofi launched its long-acting insulin Lantus (insulin glargine) in 2000, the other major providers of insulin – Eli Lilly & Co. and Novo Nordisk AS –...